Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults
Top Cited Papers
- 6 January 2005
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 352 (1) , 48-62
- https://doi.org/10.1056/nejmra041811
Abstract
Metabolic complications, including dyslipidemia, insulin resistance, and altered fat distribution (loss of subcutaneous fat and a relative increase in central fat), are common in adults infected with the human immunodeficiency virus (HIV) who are receiving highly active antiretroviral therapy (HAART). These complications may increase these patients' risk of cardiovascular disease. In this review, we discuss progress in the understanding of pathogenetic mechanisms of cardiovascular risk in this population and the development of treatment strategies.Keywords
This publication has 92 references indexed in Scilit:
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004
- Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjectsAIDS, 2003
- Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD studyAIDS, 2003
- Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapyAIDS, 2003
- Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitorsAIDS, 2003
- Alterations of Apolipoprotein B Metabolism in HIV-Infected Patients With Antiretroviral Combination TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Apoprotein C-III and E-Containing Lipoparticles Are Markedly Increased in HIV-Infected Patients Treated with Protease Inhibitors: Association with the Development of LipodystrophyJournal of Clinical Endocrinology & Metabolism, 2001
- Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and LipodystrophyClinical Infectious Diseases, 2001
- Absence of Association Between Individual Thymidine Analogues or Nonnucleoside Analogues and Lipid Abnormalities in HIV-1–Infected Persons on Initial TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalitiesThe Lancet, 1998